HANetf ICAV - iClima Smart Energy UCITS ETF (DGEN)

Overview

Deltagen Inc. is a pioneering entity in the biopharmaceutical sector, specializing in the provision of crucial drug discovery tools and services. Founded in 1999 and operating from its headquarters in San Mateo, California, the company has cemented its reputation as a key partner for pharmaceutical companies by offering advanced solutions aimed at streamlining the drug discovery process. Deltagen Inc. distinguishes itself with a strong focus on increasing the efficiency of drug discovery through its innovative programs and technologies, all while emphasizing target validation in critical health areas such as immunology and metabolic diseases.

Products and Services

Deltagen Inc. offers an array of products and services designed to expedite and optimize the drug discovery process for its clients. These offerings include:

• Biological Models: Deltagen provides access to a variety of genetically engineered animal models. These models are invaluable for preclinical studies, allowing researchers to study disease mechanisms, assess drug efficacy, and investigate safety profiles in systems that mimic human diseases.
• Small-molecule Drug Targets: Recognizing the importance of identifying and validating novel drug targets, Deltagen offers a suite of services dedicated to small-molecule drug targets. This includes the identification of potential targets and the development of assays to test small-molecule interactions, contributing significantly to the early stages of drug discovery.
• Secreted Protein Drug Targets: Alongside small-molecule targets, Deltagen also specializes in the identification and validation of secreted protein drug targets. Such proteins often play crucial roles in signaling pathways and represent an important class of therapeutics, particularly in the areas of immunology and metabolic diseases.
• Target Validation Data: A core component of Deltagen's offerings is its target validation services. By providing comprehensive data on the function and disease relevance of potential drug targets, the company empowers its clients to make informed decisions during the drug development process. This is especially pertinent in the fields of immunology and metabolic diseases, where the correct identification of targets can significantly impact the success rate of new therapies.